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Summary 
Aims: analyze ICO´s capacity in predicting hemodynamic impairment in Erectile Dysfunction 
(ED) patients, independently and integrated in Metabolic Syndrome (MetS) definitions. 
Methods: 485 ED patients followed in Urology consult from 1/2008 until 3/2012 were evaluated 
by a standardized protocol: health questionnaire, anthropometric measurements (AM), blood 
pressure and analysis, and Penile Duplex Doppler Ultrasound (PDDU) exam. Associations 
between AM and MetS definitions, including ATPIII, IDF and a new definition replacing Waist 
Circumference (WC) by ICO in ATPIII MetS definition (ModATPIII), and PDDU were 
calculated.  
Results: ICO was the measure of obesity more strongly correlated with diminished mean Peak 
Systolic Velocity (mPSV) (r=-0.189, P<0.001). A positive association remains when replacing 
WC by ICO≥0.60 in ATPIII MetS definition (ModATPIII). With ModATPIII, prevalence of MetS 
was 32.4%, 49.2% of these patients having Arterial Dysfunction (AD) in PDDU. Patients with 
ModATPIII had lower mPSV when compared to non-MetS patients (30.8 vs. 37.1, P<0.001).  
Only the IDF definition had a significant association with AD (OR=1,853 [95%CI: 1.202–2.857]). 
Conclusions: ICO revealed potential value to predict PDDU changes in a MetS context. However, 
IDF definition presented a stronger correlation with arteriogenic ED. Although longitudinal 
studies are necessary to confirm this hypothesis, our study highlights the importance of different 
MetS definitions for ED assessment. 
Keywords: Erectile Dysfunction; Index of Central Obesity; Metabolic Syndrome; Penile 
Hemodynamics; Penile Duplex Doppler Ultrasound; 
 
 
Introduction 
 
Erectile dysfunction (ED) is the consistent or recurrent inability of a man to attain and/or maintain 
a penile erection sufficient for sexual performance. [1] Being mostly vasculogenic in nature, 
mainly due to aging or underlying co-morbidity, ED can be seen as a clinical manifestation of a 
functional or structural abnormality that affects penile circulation and that is part of a more 
generalized vascular dysfunction. [2,3] This underlying concept is illustrated by a positive 
association of ED with Metabolic Syndrome (MetS), which has been shown to triple its risk. 
[3,4,5] 
The MetS, present in 27.5% of the Portuguese population[6], is defined as a set of cardiovascular 
risk factors such as obesity, insulin resistance, high blood pressure (HBP) and dyslipidemia, and 
can be seen as a low-grade chronic inflammatory state that leads to endothelial dysfunction and, in 
a sexual medicine context, hypogonadism. [5] Many definitions exist for it, being National 
Cholesterol Education Program – Adult Treatment Panel III (ATPIII) and International Diabetes 
Federation (IDF) the most used ones, with ATPIII having a reported superior correlation with 
penile blood flow impairment, low testosterone and Cardiovascular Events. [5,7] Therefore, it has 
received worldwide appraisal for its utility as a screening tool in patients with risk for events of 
cardiovascular nature. [8,9] 
From all the components of MetS, obesity (measured by bioimpedance) and HBP are the ones that 
are independently associated with a deterioration of the hemodynamic profile in Penile Duplex 
Doppler Ultrasound (PDDU) measurements. [10] Although visceral obesity is known to play a 
primordial role in the pathophysiology of MetS and ED, it is also the center of some dispute 
concerning its overvaluation in MetS definitions. [5] This way, having none of the actual MetS 
definitions considered to take visceral obesity properly into account, many new measures have 
been proposed for its evaluation, being Index of Central Obesity (ICO) one of the most acclaimed, 
as it has been shown to supplant the limitations of the traditionally used Waist Circumference 
(WC), namely by not neglecting height variation in subjects. [11,12] 
The correlation of ICO with ED, specifically with hemodynamic changes in vasculogenic ED, has 
not been yet tested. Thus, this study aims to analyze the capacity of ICO in predicting 
hemodynamic impairment in patients with ED, either independently, or integrated in the more 
commonly used MetS definitions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients and Methods 
 
The present study is of transversal, descriptive and analytical nature. The sample includes patients 
followed in our Urology consult for ED (n=485) from January 2008 until March 2012, date of the 
start of the analysis. Signed informed consent on the inclusion of their data in this study was 
obtained for all patients. Exclusion criteria were the presence of any of the following conditions: 
history of recent coronary artery disease, neurological disease, pelvic trauma, major psychiatric 
disorder, thyroid disease, hepatic disease, end-stage renal disease, and history of drug abuse. 
All patients were submitted to a standardized evaluation protocol that included a health 
questionnaire, physical examination, blood analysis and PDDU exam. The Health questionnaire 
contemplated past medical history, cardiovascular and metabolic risk factors such as High Blood 
Pressure (HBP), Diabetes mellitus, and Total cholesterol (TCho), Low-Density Lipoprotein 
(LDL), Triglycerides (TG) and/or High-Density Lipoprotein (HDL) abnormalities. 
Pharmacological history was also collected, along with alcohol and tobacco use. Physical 
examination was performed by the same technician and with patients barefoot and with light 
clothing. It contemplated systolic and diastolic blood pressure evaluation and the recording of the 
anthropometric parameters weight, height and WC. WC measurement was obtained using an 
anthropometric tape (to the nearest 0.1 cm) at the end of normal expiration at the level of the 
midpoint between the lower end of the 12th rib and upper end of iliac crest. Body Mass Index 
(BMI) was calculated by dividing the weight in kilograms by the square of the height in meters, 
and ICO by dividing WC by height, both in centimeters.  
The systolic and diastolic blood pressures were measured in the right arm using an automatic 
manometer (DINAMAP® Procare 300, GE, UK) in the sitting position after a 10-minute rest 
period. HBP was defined as present if arterial blood pressure was equal or over 130/85 mmHg. 
Blood analysis was performed from samples of venous blood collected between 8 and 10 am after 
a 12-hour overnight fasting period, and the following measurements were made by routine 
laboratory methods: blood glucose, HDL, LDL, TG, TCho. Patients were then classified according 
to three MetS definitions: ATPIII, IDF and a Modified ATP III (ModATPIII) definition. Presence 
of MetS according to ATPIII was considered if 3 or more of the following 5 conditions were 
present: WC >102cm; TG >1.7 mmol/L (150 mg/dL) or anti-hypertriglyceridemic medication; 
HDL <1.03 mmol/L (40 mg/dL) or HDL directed medication; plasma glucose ≥6.1 mmol/L (110 
mg/dL); arterial blood pressure ≥130/85 mmHg or treatment for previously diagnosed HBP. [13] 
MetS according to IDF was considered if central obesity (WC >94cm or BMI ≥30 Kg/m2) was 
present along with 2 of the following 4: TG >1.7 mmol/L or anti-hypertriglyceridemic medication; 
HDL <1.03 mmol/L or HDL directed medication; plasma glucose >5.6 mmol/L  (100 mg/dL); 
systolic blood pressure ≥130 mmHg or Diastolic blood pressure ≥85 mmHg or treatment for 
previously diagnosed HBP. [14] MetS according to our ModATP III was derived from ATPIII 
definition by substitution of the criterion WC>102cm for ICO≥0.60. ICO was calculated using the 
formula ICO = WC (cm) / Height (cm), and the adopted cut-off of ≥0.60 was based on National 
Portuguese ICO values provided by Portuguese Society of Cardiology, based on a near 17,000 
individual representative anthropometric nation-wide study. [15] 
PDDU examination was performed by the same investigator using the protocol suggested by the 
International Society for Sexual Medicine Standards Committee in Standard Practice in Sexual 
Medicine [1]. A 12 MHz transducer (GE Logic 7 Ultrasound System, UK) was used to record 
penile vascular flow patterns 5, 10 and 20 minutes after the injection of 10 to 20 mcg of 
commercial E1 Prostaglandin (Caverject®). Before and in-between evaluations, patients were left 
alone to prevent disturbances and consequent loss of sexual arousal, and asked to maintain the best 
possible erection by tactile stimulation. The mean values of Peak Systolic Velocity (mPSV), End-
Diastolic Velocity (mEDV) and Resistive Index (RI) (accordingly to the formula: RI=(PSV-
EDV)/PSV) were obtained from spectral waveform measurements. The classification criteria was 
the following: normal for mPSV >35 cm/s, EDV <5 cm/s and RI >1; arterial insufficiency for 
mPSV ≤35 cm/s; mPSV asymmetry for an asymmetry in mPSV >10 cm/s; cavernous venous-
occlusive disease for mPSV ≥35 cm/s and EDV ≥5 cm/s; mixed when 35> PSV >25 cm/s and 
EDV ≥5 cm/s. Finally, the degree of erectile response was classified according to a graded scale: 0 
(no response); 1 (minimal tumescence and no rigidity); 2 (moderate tumescence and no rigidity); 3 
(full tumescence and moderate rigidity); 4 (full rigidity). 
 
Statistical analysis   
The differences between the groups were assessed by unpaired Student’s t-test or Mann–Whitney 
U-test as appropriate for continuous variables. Multivariate analysis was performed by 
multivariate linear regression and multivariate logistic regression for continuous and categorical 
dependent variables, respectively. Odds ratio (OR) with respective 95% confidence intervals (95% 
CI) were calculated to evaluate the association of categorical variables. Pearson correlation was 
performed to evaluate the association between continuous variables. Statistical analysis was 
performed using SPSS® version 17.0 for Windows® (SPSS Inc., Chicago, IL, USA). The 
software handled missing data automatically. Statistical significance was considered at P-level < 
0.05. 
 
Results 
 
The population in study (n=485) had a mean age of 55.8 ± 11.1 years, mean weight of 79.9 ± 13.3 
Kg and a mean height of 1.7 ± 0.1 meters (mean BMI of 27.7 ± 4.2 Kg/m2). Mean ICO and WC 
were of 0.60 ± 0.07 and 101.9 ± 10.6 cm, respectively. More data about the participants is 
presented in table I. 
PDDU was normal in 30.8% of patients. Arterial Dysfunction (AD), veno-occlusive dysfunction, 
arterial dysfunction by cavernous arteries asymmetry and mixed dysfunction were identified in 
41.0%, 14.7%, 7.7% and 5.8%, respectively. MetS according to ATPIII criteria was identified in 
31.1% of the population, 48.4% of it having AD diagnosed with PDDU. On the other hand, IDF 
MetS criteria were identified in 46.5% of patients, 49.7% of them having AD diagnosed with 
PDDU. Finally, using ModATP III, the prevalence of MetS was of 32.4%, 49.2% of these having 
AD diagnosed with PDDU. The agreement (overlap) between MetS definitions was calculated, 
and the results are presented in table II. 
Patients with ATPIII and IDF MetS criteria had significantly lower mPSV comparatively to non-
MetS patients (30.9 vs. 37.3 cm/s, P<0.001; 31.2 vs. 39.3 cm/s, P<0.001, respectively). Similarly, 
patients with ModATP III MetS criteria had significantly lower mPSV when compared to non-
MetS patients (30.8 vs. 37.1, P<0.001) (Fig. 1). None of the three MetS definitions showed 
association with mean Peak Diastolic Velocity or RI changes on PDDU (data not shown). 
Multivariate analysis including the variables HBP, Hypertriglyceridemia (HTG) (serum level of 
TG >1.7mmol/L / 150mg/dl), fasting glucose >5.6 mmol/L (100 mg/dL), HDL <1.03 mmol/L, 
BMI ≥30 Kg/m2 and WC >94 cm, showed that only HBP was independently associated with 
diminished mPSV on PDDU examination (P=0.005) (Table III). 
In another model where ICO substituted for BMI, ICO and WC were also found to be 
independently associated with diminished mPSV on PDDU examination (P=0.017 and P=0.046, 
respectively) (Table III). 
ICO, when compared to WC, was found to be the measure of obesity more strongly correlated 
with diminished mPSV on PDDU (r=-0.189, P<0.001 vs. r=-0.147, P=0.003, respectively). 
An ICO over the established cut-off of 0.60 was found in 51.9% of patients. Of these, 46.0% had 
AD on Doppler measurements. The calculated OR for having AD in PDDU when having 
ICO≥0.60 was of 1.471 (95% CI: 0.986-2.194). The different MetS definitions (ATPIII, IDF and 
ModATPIII) were all found to be independent predictors of diminished mPSV in PDDU 
measurements (P=0.007, P=0.002 and P=0.008, respectively) after adjustment to age, tobacco use 
and TCho. Again, no association was found regarding EDV or RI alterations in this multivariate 
analysis. 
When comparing the three definitions in their correlation with AD in PDDU, IDF was found to 
have the only statistically significant OR (1,853 [95% CI: 1.202-2.857]). MetS ATPIII and 
ModATP III presented OR of, respectively, 1.507 (95% CI: 0.983-2.310) and 1.534 (95% CI: 
0.992-2.374).  
 
 
 
 
 
 
 
Discussion 
 
Due to the existence of several MetS definitions, their specificity, sensibility and prediction 
capability of different pathological outcomes has been widely and thoroughly studied, but their 
clinical impact is still controversial. In the particular setting of vasculogenic ED, different 
definitions have been studied and ATPIII has been found to be the one that showed the strongest 
correlation with diminished mPSV in PDDU measurements. [7] In our study, such conclusion was 
not verified as ATP III, IDF and ModATP III definitions were all found to be positively correlated 
with diminished mPSV after adjustment for confounding factors. However, from the 3 definitions, 
IDF was the one that showed an independent association with mPSV with the highest statistical 
significance (P=0.002; vs P=0.007 in ATPIII and P=0.008 in ModATPIII) and the only one to 
show a statistically significant association with AD. 
The IDF's superior correlation with Arteriogenic ED, although not consistent with the findings of 
Corona and colleagues, corroborates the results of other studies that show a superior correlation of 
IDF with pathological cardiovascular alterations such as carotid atherosclerosis and arterial 
stiffness. [7,16,17] Thus, these results constitute an upgrade on the already polemical comparison 
between MetS definitions, where studies repeatedly show conflicting results. 
Although visceral obesity has been shown to be, when compared to subcutaneous and generalized 
obesity, the one that mostly determines the deleterious effects of MetS such as ED, the most used 
MetS definitions (ATPIII and IDF) do not evaluate it properly and also disregard interindividual 
anthropometric variations such as height. [11,12,18,19]. Different anthropometric parameters of 
visceral obesity have been analysed in the context of ED, although few studies have been done to 
test these parameters in the specific setting of hemodynamic alterations in PDDU. [18] In fact, 
Riedner and colleagues have found that the anthropometric indicators of visceral obesity more 
associated with ED diagnosed by clinical history in a Brazilian population were sagittal abdominal 
diameter, sagittal abdominal diameter-height index, waist-hip ratio, WC >106 cm and WC >102 
cm. [18] Of these, the latter was found to be the strongest predictor of ED. However, when 
evaluating the predictive value of hemodynamic changes in PDDU, WC >102 cm failed to show 
such an independent association. [10] This way, although WC is the visceral obesity measure most 
used in clinical practice and in the definitions of MetS, its limitations in evaluating short-stature 
individuals suggest that it may also not be the more appropriate or predictive measure when 
evaluating penile hemodynamic changes in ED patients. [7,12,20] ICO, a nouvelle anthropometric 
measure, has been proposed not only as a more accurate measure in the evaluation of central 
obesity but also as a more accurate substitute of WC in MetS definitions. [8] Although having 
been positively correlated with insulin resistance and hypogonadism, no studies have been done so 
far to test its utility in ED. 
In this study, we have found that ICO (with a cut-off of 0.60 defined by the national median) was 
correlated with diminished mPSV in PDDU measurements, but the same has been found for WC 
and BMI although with less significant results. In a statistical model including factors such as 
HBP, HTG, HDL levels, WC, ICO and insulin resistance, only HBP and the anthropometric 
parameters ICO and WC >94cm have been shown to be independently associated with a 
diminished mPSV on PDDU measurements. ICO over 0.60 represented a 47% chance of detecting 
hemodynamic changes in PDDU exam in patients with diagnosed ED. 
Such results corroborate the findings of Tomada and colleagues regarding HBP, but also highlight 
the positive correlation of hemodynamic alterations in ED with an anthropometric parameter 
which, as far as we know, has not yet been done. [10] However, contrarily to this previous study, 
WC was also found to be independently associated with diminished mPSV. This positive 
correlation can be partly explained by the fact that a lower cut-off was used (94cm vs 102cm).  
In spite of such positive association, one must point out that the sole nature of an anthropometric 
parameter makes this correlation liable to potential confounding factors, such as morphologic 
differences between individuals. Thus, iatrogenic (p.e., corticosteroids) and pathological changes 
on fat distribution must also be considered when anthropometrically evaluating an individual. 
Taking into account the positive correlation of both WC and ICO with penile AD, ICO revealed to 
be more strongly associated with diminished mPSV on PDDU. Bearing in mind the positive 
associations of ICO with penile hemodynamic changes, our study suggests that ICO might be 
more appropriate than the traditional WC in predicting hemodynamic changes when evaluating 
patients with ED. This finding is especially useful in populations in which there is a higher 
prevalence of individuals of short stature, which are especially prone to adverse cardiovascular 
events and whose central obesity is not correctly evaluated by WC. [19,21] In fact, in patients with 
short stature, WC is not the best way to infer visceral obesity, as it may be increased due to the 
decreased height of the subject. This is also valid in the elderly population, in which there is a 
decrease of height with age. ICO also outstands WC on the strength of correlation with insulin 
resistance, while simultaneously maintaining its simplicity of calculation. [8] 
The transversal nature of this study and the fact that the study only included patients with ED does 
not allow us to state that ICO is a predictive measure of ED. Indeed, although it is proposed as a 
more accurate measure of visceral obesity, further representative longitudinal studies comparing 
the different visceral obesity measures are necessary to clarify this question. [12] 
Concerning the adopted ICO cut-off value, it is possible to observe that our study´s median ICO 
and national-based ICO are similar (0.60). This proximity is maintained not only when sub-
analyzing the national data in the 50-59 age group (in which this study’s median age is included), 
but also at a district level. In fact, 50-59 age group ICO´s values were exactly the same as the 
entire adult population (0.60), and the Porto´s district value was of 0.59. Although the national 
ICO was obtained from a statistically representative nation-wide population, it is not completely 
correct to present it as a national cut-off as it was obtained from a primary health-care seeking 
population. Thus, it might be an overestimation of national values, and hence its proximity to our 
ED population´s ICO.  Indeed, when comparing our ICO cut-off to the ones suggested by Parikh 
and colleagues for other Mediterranean countries based on WC cut-offs suggested by IDF, one can 
notice that our proposed Portuguese population´s ICO is above of the values for these countries 
(ex: Spain: 0.54; Italy: 0.53), which have rather similar genetics and eating habits. [12,22,23] On 
the other hand, it is rather proximal to USA and Canada values (0.58). Nevertheless, one must 
note that these countries’ suggested ICO was not based on the measurement of height and WC by 
a single study, but rather on the conjugation of separate results by different studies. Therefore, 
data may not be correct at the individual level. This cut-off seeking limitation is one of the 
principal difficulties of ICO usage, as pointed out by Parikh and colleagues. [12] Despite the 
discussion about the ICO´s cut-off value, it is clear that when analyzed as a continuous variable it 
has an important correlation with mPSV. 
 
In conclusion, ICO has been shown to be the measure of obesity more strongly correlated with 
hemodynamic changes in Penile Doppler Measurements. Its integration in the traditional MetS 
definitions has also been shown to be associated with penile hemodynamic changes in an ED 
setting.  
In spite of such association, the integration of ICO in the MetS definition has not been found to 
increase the prediction capability of Penile Hemodynamic results compared to the traditional MetS 
definitions. Other studies are necessary to confirm these findings. 
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I – Figure 1 
	  
Title and Caption: 
Figure 1 – Penile Doppler Duplex Ultrasound mean Peak Systolic Velocity with/without 
diagnosis of  Metabolic Syndrome using different definitions. 
 
* - P< 0.001 
NCEP-ATP III = National Cholesterol Education Program - Adult Treatment Panel III; 
ModATP III – Modified definition of National Cholesterol Education Program - Adult 
Treatment Panel III; IDF = International Diabetes Federation; PDDU mPSV – Penile 
Duplex Doppler Ultrasound mean Peak Sistolic Velocity 
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II	  –	  Tables	  
Table I – Description of the population in study. 
 
Variable Description Value 
Total population (n)  485 
Age (years)  55.8 ± 
11.1 
Weight (Kg)  79.9 ± 
13.3 
Height (meters)  1.7 ± 0.1  
WC (centimeters)  101.9 ± 
10.6 
ICO ICO = WC (cm) / Height (cm) 0.60 ± 
0.07 
BMI (Kg/m2)  27.7 ± 4.2 
IIEF-5 Score  11.7 ± 4.7 
Metabolic Syndrome (NCEP-ATPIII 
Criteria) (%) 
 31.1 
Metabolic Syndrome (IDF Criteria) (%)  46.5 
Metabolic Syndrome (Modified NCEP-
ATPIII) (%) 
 32.2 
Metabolic Syndrome Components (%) HBP (≥ 130/85mmHg) or 
treatment 
49.3 
 Hypertriglyceridemia (≥1.7 
mmol/L; 150 mg/dL;) 
29.6 
 Insulin Resistance (ATP III) (≥6.1 
mmol/L / 110 mg/dL) 
33.9 
 Insulin Resistance (IDF) (>5.6 
mmol/L / 100 mg/dL) 
78.5 
 Low HDL (<1.03 mmol/L; 40 
mg/dL) 
25.4 
 WC (ATP III) > 102 cm 52.1 
 WC (IDF) > 94 cm / BMI ≥ 30 80.1 / 23.0 
Tobacco (%) Smoker 23.3 
 Ex-Smoker 33.5 
 Non-Smoker 43.2 
Current Medication (%) Anti-Aggregant Agent 27.5 
 Beta-Blocker 17 
 AR Blockers 17.2 
 ACE Inhibitors 22.5 
 Calcium Channel Blockers 16.5 
 Thyazidic Diuretics 16.7 
 Antidepressants 9.5 
 Benzodiazepines 18 
 Statins 36.2 
 Nitrates 4.7 
 Fibrates 7 
 Warfin 3.1 
Penile Curvature (%)  8 
Data are expressed as mean ± standard deviation when in normal distribution and as 
percentage when categorical. 
ICO = Index of Central Obesity; BMI = Body Mass Index; IIEF-5 = Abridged 5-item 
version of the International Index of Erectile Function; ATP III = National Cholesterol 
Education Program - Adult Treatment Panel III; ModATP III = Modified definition of 
National Cholesterol Education Program - Adult Treatment Panel III; IDF = International 
Diabetes Federation; HBP = High Blood Pressure; HDL = High-density Lipoprotein; AR = 
Angiotensin Receptor; ACE = Angiotensin-Converting Enzyme; WC = Waist 
Circumference. 
 
 
 
 
 
 
 
Table II – Overlap between different MetS definitions. 
 
MetS 
Definition 
Positive 
Concordance 
IDF (%) 
Negative 
Concordance 
IDF (%) 
Positive 
Concordance 
ModATP III 
(%) 
Negative 
Concordance 
ModATP III 
(%) 
ATP III 75.4 98.5 89.9 97.4 
ModATP 
III 96.9 81.7  
 
MetS = Metabolic Syndrome; ATP III = National Cholesterol Education Program - Adult 
Treatment Panel III; ModATP III = Modified definition of National Cholesterol Education 
Program - Adult Treatment Panel III; IDF = International Diabetes Federation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table III – Multivariate analysis to evaluate the independent association of the Metabolic 
Syndrome  criteria to a diminished mean Peak Systolic Velocity (mPSV) on Penile 
Doppler Duplex Ultrasound (PDDU) examination. 
 
Model 1  Model 2 
Variable 
Beta 
Coefficien
t 
P 
valu
e 
 
Variable 
Beta 
Coefficien
t 
P 
valu
e 
HBP  
(>130/85mmHg) 
-0.214 0.005 
 HBP 
(>130/85mmHg) -0.190 0.012 
Hypertriglyceridemi
a (>1.7 mmol/L) -0.027 0.726 
 Hypertriglyceridemi
a (>1.7 mmol/L) -0.038 0.615 
Fasting Glucose 
(>5.6 mmol/L) -0.087 0.236 
 Fasting Glucose 
(>5.6 mmol/L) -0.073 0.318 
HDL (<1.03 
mmol/L) 0.004 0.962 
 HDL (<1.03 
mmol/L) 0.000 0.995 
BMI over 30 -0.086 0.253  ICO ≥ 0.60 -0.210 0.017 
WC > 94 cm 0.081 0.286  WC > 94 cm 0.173 0.046 
 
HBP = High Blood Pressure; HDL = High Density Lipoprotein; BMI = Body Mass Index; 
ICO = Index of Central Obesity 
Model 1 – Multivariable analysis testing independent association of 6 different variables 
with diminished Mean Peak Systolic Velocity (mPSV) in Penile Doppler Duplex 
Ultrasound.  
Model 2  - Multivariable analysis model based on Model 1, with substitution of BMI for 
ICO.  
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IV – Strobe Checklist 
STROBE Statement—Checklist of items that should be included in reports of cross-
sectional studies  
 
 Item 
No Recommendation 
Title and 
abstract 
1 (a) Indicate the study’s design with a commonly used 
term in the title or the abstract 
(b) Provide in the abstract an informative and 
balanced summary of what was done and what was 
found 
Introduction 
Background/r
ationale 
2 Explain the scientific background and rationale for the 
investigation being reported 
Objectives 3 State specific objectives, including any prespecified 
hypotheses 
Methods 
Study design 4 Present key elements of study design early in the 
paper 
Setting 5 Describe the setting, locations, and relevant dates, 
including periods of recruitment, exposure, follow-up, 
and data collection 
Participants 6 (a) Give the eligibility criteria, and the sources and 
methods of selection of participants 
Variables 7 Clearly define all outcomes, exposures, predictors, 
potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and 
details of methods of assessment (measurement). 
Describe comparability of assessment methods if 
there is more than one group 
Bias 9 Describe any efforts to address potential sources of 
bias 
Study size 10 Explain how the study size was arrived at 
Quantitative 
variables 
11 Explain how quantitative variables were handled in 
the analyses. If applicable, describe which groupings 
were chosen and why 
Statistical 
methods 
12 (a) Describe all statistical methods, including those 
used to control for confounding 
(b) Describe any methods used to examine subgroups 
and interactions 
(c) Explain how missing data were addressed 
(d) If applicable, describe analytical methods taking 
account of sampling strategy 
(e) Describe any sensitivity analyses 
Results 
Participants 13* (a) Report numbers of individuals at each stage of 
study—eg numbers potentially eligible, examined for 
eligibility, confirmed eligible, included in the study, 
completing follow-up, and analysed 
(b) Give reasons for non-participation at each stage 
(c) Consider use of a flow diagram 
Descriptive 
data 
14* (a) Give characteristics of study participants (eg 
demographic, clinical, social) and information on 
exposures and potential confounders 
(b) Indicate number of participants with missing data 
for each variable of interest 
Outcome data 15* Report numbers of outcome events or summary 
measures 
Main results 16 (a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their precision (eg, 
95% confidence interval). Make clear which 
confounders were adjusted for and why they were 
included 
(b) Report category boundaries when continuous 
variables were categorized 
(c) If relevant, consider translating estimates of 
relative risk into absolute risk for a meaningful time 
period 
Other 
analyses 
17 Report other analyses done—eg analyses of 
subgroups and interactions, and sensitivity analyses 
Discussion 
Key results 18 Summarise key results with reference to study 
objectives 
Limitations 19 Discuss limitations of the study, taking into account 
sources of potential bias or imprecision. Discuss both 
direction and magnitude of any potential bias 
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence 
Generalisabil
ity 
21 Discuss the generalisability (external validity) of the 
study results 
Other information 
Funding 22 Give the source of funding and the role of the funders 
for the present study and, if applicable, for the 
original study on which the present article is based 
 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives 
methodological background and published examples of transparent reporting. The 
STROBE checklist is best used in conjunction with this article (freely available on 
the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal 
Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). 
Information on the STROBE Initiative is available at www.strobe-statement.org. 
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